A tetrasubstituted 29-residue GHRH analogue without the albumin-binding Drug Affinity Complex.
The 200 mcg nightly, five-days-on/two-days-off entry describes the calculator library, not a tested human no-DAC regimen. This is educational source context, not a protocol or recommendation.
There is no regulator-approved starting dose for this research use. A low-looking number is not automatically safe.
This is the range represented in the in-app protocol library. It describes the source record; it does not validate the regimen.
Higher exposure is not established as more effective. Human pharmacokinetic and long-term safety data may be absent.
Confirm the exact molecule before calculating: “CJC-1295” labels may refer to incompatible DAC and no-DAC forms.
The cadence represented by the recorded calculator presets.
Published experiments may use a different route, formulation, timing, or population and should not be treated as interchangeable.
No single schedule has been validated across products or research contexts.
The best-known human CJC-1295 trial used the long-acting DAC conjugate; it does not validate this preset.
Keep cold, dry, and protected from light according to the manufacturer certificate or validated lab SOP.
Use sterile technique, refrigerate as validated, and avoid repeated freeze-thaw cycles.
Record lot, concentration, preparation date, and the identity/purity documentation used by the lab.
What published studies and recent community write-ups report about amounts, timing and course length. 2 clinical and 4 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Clinical2 rows | |||||
| CJC-1295 with DAC, ascending single and repeated doses (not the no-DAC peptide)Healthy adults aged 21-61 in two placebo-controlled trials | Four ascending single doses, with 30 and 60 mcg/kg described as the best tolerated | Single injection, or two to three injections weekly or every two weeks | Subcutaneous | 28 days (single-dose study) and 49 days (repeat-dose study)Not applicable | Journal of Clinical Endocrinology and Metabolism (PubMed)2006 |
| A single injection raised mean growth hormone 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for 9-11 days, with an estimated half-life of 5.8-8.1 days and IGF-1 still elevated 28 days after repeated doses. These results belong to the albumin-bound DAC molecule; the no-DAC peptide is cleared in minutes to an hour and would not reproduce a week-long effect. | |||||
| CJC-1295 with DAC, overnight GH pulsatility study (not the no-DAC peptide)Healthy men aged 20-40 | 60 or 90 mcg/kg | Single injection, sampled every 20 minutes overnight before and one week after | Subcutaneous | One weekNot applicable | Journal of Clinical Endocrinology and Metabolism (PubMed)2006 |
| A week after one dose, trough growth hormone was 7.5 times higher, mean GH was up 46% and IGF-1 up 45%, while the number and size of GH pulses were unchanged. The two doses performed the same, and the authors attributed the IGF-1 rise to the elevated trough rather than bigger pulses. | |||||
| Community-reported4 rows | |||||
| Community saturation-dose protocol with a GHRP | 100 mcg (about 1 mcg/kg) per injection, paired with 100 mcg ipamorelin | 1-3 times daily, fasted; bedtime dose described as the most important | Subcutaneous | 3-6 months or longer described as toleratedNone required in this source's view | Community resource2026 |
| This 2026 guide treats roughly 100 mcg as the dose that saturates pituitary GHRH receptors for one pulse, so it adds injections rather than raising the single dose, and insists on dosing at least 2 hours after food and 30-60 minutes before eating. It acknowledges that Mod GRF 1-29 as a specific compound has little published trial data and leans on GHRH and CJC-1295 pharmacology instead. | |||||
| Community step-up framework | 100 mcg once daily to start, stepping up by 50 mcg every 1-2 weeks toward 200 mcg daily; 100-300 mcg per injection overall | 1-3 times daily in fasted windows, pre-bed first | Subcutaneous | 8-12 weeks4-6 weeks off, or 5 days on and 2 days off each week | Community resource2026 |
| A 2026 vendor-affiliated guide starts with a single pre-bed dose to check tolerance and adds a second daily injection before pushing any single dose past 200 mcg. It states that no human trial has tested the No DAC variant at protocol scale and that its patterns are extrapolated from CJC-1295 and GHRH research. | |||||
| Clinic protocol with ipamorelin | 100 mcg of each peptide per dose to start, titrated to 200-300 mcg of each | Once daily at bedtime on an empty stomach, 5 days per week; sometimes split into 2-3 daily injections | Subcutaneous with an insulin syringe | 8-12 weeksA break after each cycle, then reassessment with labs | Community resource2026 |
| A Los Angeles aesthetic clinic's 2026 page describes how its prescribers pair the no-DAC peptide with ipamorelin and contrasts it with CJC-1295 with DAC at 1-2 mg once or twice weekly. It states there is no FDA-approved label for the combination and that the figures are provider-directed practice rather than a prescription. | |||||
| Community cycle table | 100 mcg per injection, with 100-200 mcg ipamorelin | 1-2 times daily (beginner) to 3 times daily (fasted morning, post-workout, bedtime) | Subcutaneous, same syringe as the GHRP | 8-16 weeks4 weeks off | Community resource2026 |
| This 2026 guide quotes a half-life of about 30 minutes for the no-DAC peptide against 8 days for the DAC form and keeps every tier at 100 mcg of Mod GRF while varying the GHRP dose and injection count. It rates the evidence as human trials on GRF 1-29 plus animal and laboratory data on the modified analogs. | |||||
Community frameworks begin with 100 mcg injected 20-30 minutes before sleep on an empty stomach, timed to the largest natural GH pulse of the night, usually together with an equal dose of ipamorelin. Flushing and a warm face for a few minutes are the commonly described acute effects.
Rather than raise the 100 mcg dose, guides add a fasted morning injection and sometimes a post-workout one, since they treat 1 mcg/kg as the point where more peptide adds little GH. Sleep changes and water retention are the early reports.
Two or three daily pulses continue for 8-12 weeks (some sources stretch to 16), with clinics checking IGF-1 and glucose along the way and titrating both peptides together toward 200-300 mcg. Body composition claims in this window are user reports with no trial behind them.
Sources describe either 4-6 weeks off after the cycle or a weekly 5-days-on, 2-days-off rhythm, giving receptor sensitivity as the rationale. Nothing has tested whether pituitary responsiveness to this peptide actually declines.
The only human studies of this backbone used CJC-1295 with DAC: single 30-90 mcg/kg injections (2-6 mg for a 70 kg adult) that kept GH and IGF-1 elevated for one to two weeks, repeated weekly or every other week for up to seven weeks. No multi-week daily course of the no-DAC peptide has been studied in people.
Plus 4 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
ModGRF 1-29 is the 29-residue growth hormone-releasing hormone fragment GRF(1-29) with four amino acid substitutions that ConjuChem introduced in the early 2000s to resist breakdown by DPP-4 and oxidation; it is the peptide half of CJC-1295, which adds a maleimidopropionyl group on an extra lysine so the drug binds albumin and lasts about a week, hence the community names CJC-1295 without DAC or No DAC. The modified fragment itself was characterized in rat pituitary cells and rats during CJC-1295 development, and every human trial used the albumin-binding DAC version, so there is no published human dosing, pharmacokinetic or safety study of the no-DAC peptide. It is sold as a research chemical and used almost always alongside a ghrelin-receptor peptide such as ipamorelin; WADA prohibits GHRH analogues including CJC-1295 at all times, and the FDA listed CJC-1295 among compounding substances that may present significant safety risks from September 2023 until the nomination was withdrawn in April 2026.
These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.
The modified 1-29 backbone is designed to retain pituitary GHRH activity.
Four substitutions aim to slow enzymatic degradation relative to native GRF(1-29).
Short exposure is discussed in relation to endogenous GH pulses.
DAC-linked and no-DAC products have fundamentally different pharmacokinetics.
Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.
Preclinical work characterized modified GRF analogues and the later albumin-bound DAC construct.
The frequently cited 2006 trial tested long-acting CJC-1295 with DAC, not the no-DAC form (ModGRF 1-29).
Direct controlled human pharmacokinetic and outcomes data for the no-DAC product are sparse.
These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
Modified GRF (1-29), Mod GRF 1-29, CJC-1295 without DAC, CJC-1295 No DAC, Tetrasubstituted GRF(1-29), [D-Ala2, Gln8, Ala15, Leu27]-hGRF(1-29)-NH2, CAS 446036-97-1 (second registry number listed by PubChem)
XOZMWINMZMMOBR-HRDSVTNWSA-N
Protease-resistant GHRH backbone without the DAC linker
(3S)-4-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-4-oxobutanoic acid
2 curated references, each with its journal, year and study model, plus 4 community resources reported but not linked.